Meningeal carcinomatosis in breast cancer: prognostic factors and outcome

• Published in: Journal of neuro-oncology 2011-09, Vol.104 (2), p.565-572
• Main Authors: de Azevedo, Carla Rameri Alexandre Silva, Cruz, Marcelo Rocha Sousa, Chinen, Ludmilla Thomé Domingos, Peres, Stela Verzinhasse, Peterlevitz, Marcos Aurélio, de Azevedo Pereira, Artur Eugênio, Fanelli, Marcello Ferretti, Gimenes, Daniel Luiz
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Agents - therapeutic use; Breast cancer; Breast Neoplasms - mortality; Breast Neoplasms - pathology; Breast Neoplasms - therapy; Carcinoma, Ductal, Breast - mortality; Carcinoma, Ductal, Breast - pathology; Carcinoma, Ductal, Breast - therapy; Clinical Study – Patient Study; Combined Modality Therapy; Female; Humans; Kaplan-Meier Estimate; Medicine; Medicine & Public Health; Meningeal Carcinomatosis - mortality; Meningeal Carcinomatosis - secondary; Meningeal Carcinomatosis - therapy; Middle Aged; Neoplasm Staging; Neurology; Oncology; Prognosis; Radiotherapy; Treatment Outcome
• ISSN: 0167-594X; 1573-7373
• DOI: 10.1007/s11060-010-0524-y

Meningeal carcinomatosis (MC) occurs in up to 5% of breast cancer patients. Few studies have evaluated prognostic markers in breast cancer patients with MC. Our aim was to describe the treatment of breast cancer patients with MC, and identify prognostic factors related to survival. Sixty breast cancer patients that had a diagnosis of MC between January 2003 and December 2009 were included. The median age was 46 years (range 27–76). Most patients had invasive ductal carcinoma (78.3%) and high histological/nuclear grade (61.7/53.3%). Estrogen and progesterone receptors were positive in 51.7 and 43.3% of patients, respectively, and 15% were HER-2-positive. Symptoms at presentation were headache, cranial nerve dysfunction, seizures, and intracranial hypertension signals. Diagnosis was made by CSF cytology in 66.7% of cases and by MRI in 71.7%. Intrathecal (IT) chemotherapy was used in 68.3% of patients, and 21.6% received a new systemic treatment (chemo- or hormone therapy). Median survival was 3.3 months (range 0.03–90.4). There was no survival difference according to age, nuclear grade, hormonal and HER-2 status, CSF features, sites of metastasis, systemic and IT chemotherapy, or radiotherapy. However, histological grade and performance status had a significant impact on survival in the multivariate analysis. Only four papers have addressed prognostic factors in breast cancer patients with MC in the last two decades. The results of those reports are discussed here. High histological grade and poor performance status seem to impact survival of breast cancer patients with MC. Prospective studies are necessary to clarify the role of IT and systemic treatment in the treatment of those patients.